216 related articles for article (PubMed ID: 22698079)
1. Glycaemic variability and pancreatic β-cell dysfunction.
Kohnert KD; Freyse EJ; Salzsieder E
Curr Diabetes Rev; 2012 Sep; 8(5):345-54. PubMed ID: 22698079
[TBL] [Abstract][Full Text] [Related]
2. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.
Cavalot F
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():3-8. PubMed ID: 24034513
[TBL] [Abstract][Full Text] [Related]
3. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics.
Ceriello A; Esposito K; Ihnat M; Thorpe J; Giugliano D
Diabet Med; 2010 Aug; 27(8):911-7. PubMed ID: 20653749
[TBL] [Abstract][Full Text] [Related]
4. Effect of glucose variability on pathways associated with glucotoxicity in diabetes: Evaluation of a novel in vitro experimental approach.
Kuricová K; Pácal L; Šoupal J; Prázný M; Kaňková K
Diabetes Res Clin Pract; 2016 Apr; 114():1-8. PubMed ID: 27103362
[TBL] [Abstract][Full Text] [Related]
5. Honokiol protects pancreatic β cell against high glucose and intermittent hypoxia-induced injury by activating Nrf2/ARE pathway in vitro and in vivo.
Li CG; Ni CL; Yang M; Tang YZ; Li Z; Zhu YJ; Jiang ZH; Sun B; Li CJ
Biomed Pharmacother; 2018 Jan; 97():1229-1237. PubMed ID: 29145148
[TBL] [Abstract][Full Text] [Related]
6. Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.
Van Dalem A; Demeester S; Balti EV; Decochez K; Weets I; Vandemeulebroucke E; Van de Velde U; Walgraeve A; Seret N; De Block C; Ruige J; Gillard P; Keymeulen B; Pipeleers DG; Gorus FK;
Diabetologia; 2015 Dec; 58(12):2753-64. PubMed ID: 26409458
[TBL] [Abstract][Full Text] [Related]
7. Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better".
Kaneto H; Matsuoka TA; Kimura T; Obata A; Shimoda M; Kamei S; Mune T; Kaku K
J Diabetes; 2016 Mar; 8(2):183-9. PubMed ID: 26223490
[TBL] [Abstract][Full Text] [Related]
8. Syzygium cumini ameliorates insulin resistance and β-cell dysfunction via modulation of PPAR, dyslipidemia, oxidative stress, and TNF-α in type 2 diabetic rats.
Sharma AK; Bharti S; Kumar R; Krishnamurthy B; Bhatia J; Kumari S; Arya DS
J Pharmacol Sci; 2012; 119(3):205-13. PubMed ID: 22786584
[TBL] [Abstract][Full Text] [Related]
9. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
van Raalte DH; Verchere CB
Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
[TBL] [Abstract][Full Text] [Related]
10. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hyperglycaemia in newly diagnosed diabetic patients is associated with a reduction in oxidative stress and improvement in β-cell function.
Acharya JD; Pande AJ; Joshi SM; Yajnik CS; Ghaskadbi SS
Diabetes Metab Res Rev; 2014 Oct; 30(7):590-8. PubMed ID: 24459082
[TBL] [Abstract][Full Text] [Related]
12. [Anatomical and functional plasticity of pancreatic beta-cells and type 2 diabetes].
Cerasi E; Ktorza A
Med Sci (Paris); 2007 Oct; 23(10):885-94. PubMed ID: 17937902
[TBL] [Abstract][Full Text] [Related]
13. β-Cell protection and antidiabetic activities of Crassocephalum crepidioides (Asteraceae) Benth. S. Moore extract against alloxan-induced oxidative stress via regulation of apoptosis and reactive oxygen species (ROS).
Bahar E; Akter KM; Lee GH; Lee HY; Rashid HO; Choi MK; Bhattarai KR; Hossain MM; Ara J; Mazumder K; Raihan O; Chae HJ; Yoon H
BMC Complement Altern Med; 2017 Mar; 17(1):179. PubMed ID: 28356096
[TBL] [Abstract][Full Text] [Related]
14. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
[TBL] [Abstract][Full Text] [Related]
16. The impairment of glucose-stimulated insulin secretion in pancreatic β-cells caused by prolonged glucotoxicity and lipotoxicity is associated with elevated adaptive antioxidant response.
Fu J; Cui Q; Yang B; Hou Y; Wang H; Xu Y; Wang D; Zhang Q; Pi J
Food Chem Toxicol; 2017 Feb; 100():161-167. PubMed ID: 28027979
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiological basis for intensive insulin replacement.
Rolla A
Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S3-7. PubMed ID: 15306831
[TBL] [Abstract][Full Text] [Related]
18. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
Mu PW; Chen YM; Lu HY; Wen XQ; Zhang YH; Xie RY; Shu J; Wang MM; Zeng LY
Diabetes Metab Res Rev; 2012 Mar; 28(3):236-40. PubMed ID: 21898754
[TBL] [Abstract][Full Text] [Related]
19. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
20. Insulin and atherosclerosis: how are they related?
Monnier L; Hanefeld M; Schnell O; Colette C; Owens D
Diabetes Metab; 2013 Apr; 39(2):111-7. PubMed ID: 23507269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
